These Analysts Increase Their Forecasts On Praxis Precision Medicines After Q2 Results
These Analysts Increase Their Forecasts On Praxis Precision Medicines After Q2 Results
PRAX shares fell 1.7% to trade at $51.33 on Wednesday.Praxis Precision Medicines, Inc. (NASDAQ:PRAX) reported a loss for the second quarter on Tuesday.
Praxis Precision Medicines, Inc. (納斯達克:PRAX)週二公佈了第二季度的虧損。
The company posted a quarterly loss of $1.74 per share which beat the analyst consensus estimate for a loss of $2.31 per share. The company reported quarterly sales of $357.000 thousand which missed the analyst consensus estimate of $870.000 thousand.
公司每股公佈了1.74美元的季度虧損，超過了分析師預期的每股2.31美元的虧損。公司公佈了357000美元的季度銷售額，低於分析師預期的870000美元。
"In the second quarter we continued to advance our entire portfolio, and we are poised to soon have up to four programs in registrational stage. The Essential3 program continues to progress well, with a pre-planned interim analysis of Study 1 to be conducted later this year. We remain on track for a successful topline readout enabling an NDA filing in 2025," said Marcio Souza, president and chief executive officer of Praxis. "We look forward to sharing topline results of the EMBOLD study for relutrigine, formerly known as PRAX-562, in SCN2A and 8A patients later this quarter and believe these indications could be the tip of the iceberg for future application of PRAX-562 in other DEEs."
Praxis的總裁兼首席執行官Marcio Souza說:"在第二季度，我們繼續推進整個產品組合，很快將會有多達四個申請登記階段的項目。Essential3項目仍然順利，預計今年晚些時候將進行預先計劃的研究1中期分析。我們仍然按計劃進行，以使頂線數據後在2025年提交新藥申請(NDA)", "我們期待在這個季度後期分享relutrigine(以前稱爲PRAX-562)在SCN2A和8A患者中EMBOLD研究的頂線結果，並認爲這些指標可能只是PRAX-562在其他DEE應用的冰山一角。
PRAX shares fell 1.7% to trade at $51.33 on Wednesday.
週三，PRAX股票下跌1.7%，報51.33美元。
These analysts made changes to their price targets on PRAX following earnings announcement.
這些分析師在收益公告後對PRAX的價格目標進行了調整。
- Wedbush analyst Laura Chico maintained Praxis Precision Medicine with a Neutral rating and raised the price target from $40 to $48.
- Guggenheim analyst Yatin Suneja maintained the stock with a Buy rating, while increasing the price target from $155 to $170.
- Oppenheimer analyst Francois Brisebois reiterated Praxis Precision Medicine with an Outperform rating and maintained a price target of $134.
- Needham analyst Ami Fadia reiterated the stock with a Buy and maintained a price target of $145.
- Wedbush分析師Laura Chico保持Praxis Precision Medicine的中立評級，並將價格目標從40美元升至48美元。
- Guggenheim分析師Yatin Suneja保持買入評級，將價格目標從155美元升至170美元。
- Oppenheimer分析師Francois Brisebois重申Praxis Precision Medicine的跑贏大盤評級，並維持134美元的價格目標。
- Needham分析師Ami Fadia重申買入評級，並維持145美元的價格目標。
Read More:
更多閱讀：
- Wall Street's Most Accurate Analysts Weigh In On 3 Tech Stocks With Over 3% Dividend Yields
- 華爾街最準確的分析師們對3只科技股的股息收益率超過3％進行了權衡
Considering buying PRAX stock? Here's what analysts think:
考慮購買PRAX股票？以下是分析師的看法：
